Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
about
Bacterial Infections in Hematopoietic Stem Cell Transplant RecipientsNew Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological MalignanciesThe European Hematology Association Roadmap for European Hematology Research: a consensus documentProphylactic Measures During Induction for Acute Myeloid Leukemia.European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in LeukemiaRecent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.The use of intravenous antibiotics at the onset of neutropenia in patients receiving outpatient-based hematopoietic stem cell transplantsBloodstream infections in neutropenic cancer patients: A practical update.Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated, Central Line-Associated Bloodstream Infections From Oncology Settings, 2009-2012.Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis.Prophylaxis with levofloxacin: impact on bacterial susceptibility and epidemiology in a hematopoietic stem cell transplant unitDosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.Phagosome as the organelle linking innate and adaptive immunity.Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and OncolManagement of chemotherapy-induced neutropenic fever.Life-threatening hemorrhagic pneumonia caused by Stenotrophomonas maltophilia in the treatment of hematologic diseases.Antibiotic resistance in cancer patients.Evaluation of empiric antibiotic de-escalation in febrile neutropenia.Ciprofloxacin selects for RNA polymerase mutations with pleiotropic antibiotic resistance effects.Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis.Epidemiology of bloodstream infections after myeloablative and non-myeloablative allogeneic hematopoietic stem cell transplantation: A single-center cohort study.Fluoroquinolone prophylaxis: worth the cost?Emerging resistant bacteria strains in bloodstream infections of acute leukaemia patients: results of a prospective study by the Rete Ematologica Lombarda (Rel).Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.Management of infection and febrile neutropenia in patients with solid cancer.A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia.Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea.
P2860
Q26799576-E75E363C-59B4-4C4D-BC69-EBCD35B21CD6Q26799580-A23E1C00-2FD6-4A1E-98A9-3FDB81CD2531Q28830861-5C029951-928D-48AF-8C6B-35FEFBB4D8D8Q30235496-E43932DD-3A8A-4D86-AF48-F982A2EF558EQ34390823-0AD6F5F2-DF02-48D4-97CC-3E95FB4D1B42Q34564797-B9FB35B6-CB64-4D57-83FE-EB74F654D807Q34667166-6D664668-29B2-4569-A922-97B0AB6ABA2BQ36287292-2C36A2B1-AC14-498C-AFA8-9E852CAE3375Q36913345-83C42309-1CAE-4018-93D9-2589DCC723C4Q36973200-CF473675-1643-4914-BF66-8BA984DD5DCCQ37504803-195B164D-23A3-4E04-8C9C-FDC9A5E87800Q37628616-E0578303-D2C4-4B33-8417-459AC52A6677Q37988861-E5B20F21-9076-476F-9F51-5F2739AFAD23Q38009351-ECB15A5D-27C7-4C3C-AB66-D16339798B4AQ38081793-DCA54902-28C2-4A06-A7D0-CFAEA773898DQ38087195-499B0B36-33D4-41A3-8CA2-B28AD083F289Q38188881-102BF200-C302-45AE-8D52-06835886494EQ38212258-CFEA3DCF-19C5-4C3F-9A3D-E21CB2DAFC19Q38557837-DBC4078C-412E-4A7A-B750-39FC9A1B7AEFQ39398298-0B1E072A-284D-457B-A78C-87FE49C424F9Q40129165-716D4271-DCC1-4503-91AF-3741CD6404DEQ40179367-AB9815AE-B6BA-4BD0-92AD-4605050572FFQ40272325-112A9B3E-596B-4A0C-921D-4186CEB71F48Q40469049-2DAE5A6E-671C-40DA-B0AE-24EAAC60F449Q40595836-C7FEF63B-51A5-461E-B6EA-0B7E8D41A146Q40906626-A22B973F-15B4-471D-9885-FFD213351061Q50080905-B4D699CE-D541-43DB-92AF-9BAA2CACAE69Q52728829-2B6B7C12-EC3D-4C7D-BC3B-59D1FDE855AB
P2860
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
@en
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
@nl
type
label
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
@en
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
@nl
prefLabel
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
@en
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
@nl
P1476
Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients.
@en
P2093
Eric James Bow
P304
P356
10.1097/QCO.0B013E32834CF054
P577
2011-12-01T00:00:00Z